Pasithea Therapeutics Corp. KTTA

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close 0.40 2026-10-23
Market cap $13.5M 2026-06-30 share count
52-week range 0.28 - 2.06

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.91

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Revenue ———$486.6K$15.1K—
Cost of revenue ———$113.2K$17.3K—
Gross profit ———$373.4K-$2.2K—
R&D $8.0M$7.2M$8.1M$2.7M——
SG&A $12.9M$7.1M$7.9M$9.9M$4.5M—
Total operating expenses ———$697.1K——
Operating income -$20.9M-$14.2M-$16.0M-$12.6M-$4.5M—
Interest expense ———$102$508—
Pre-tax income -$20.4M-$13.9M-$15.5M-$11.7M-$2.2M—
Net income -$20.4M-$13.9M-$16.0M-$13.9M-$2.2M—
EPS, basic -2.91-12.69-0.42-1.76-0.21—
EPS, diluted -2.91-12.69-0.42-1.76-0.21—
Shares, diluted (wtd. avg.) 7.0M1.1M1.2M1.3M10.4M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents $55.2M$6.9M$16.3M$33.1M$52.9M$243.7K
Total current assets $56.5M$7.4M$16.7M$34.1M$53.3M$248.0K
Property, plant and equipment —$122.3K$141.2K$125.2K$20.1K—
Goodwill —$1.3M$1.3M$1.3M——
Other intangibles $2.9M$7.3M$7.9M$8.6M——
Total assets $60.2M$16.1M$26.1M$45.2M$53.3M$248.0K
Accounts payable $1.1M$1.1M$2.6M$1.5M$447.3K$6.6K
Total current liabilities $5.0M$1.1M$2.6M$1.9M$447.3K$6.6K
Total liabilities $5.0M$1.3M$2.7M$2.7M$1.9M$6.6K
Retained earnings -$70.0M-$49.6M-$35.3M-$19.4M-$2.2M-$41.0K
Total equity $55.2M$14.8M$23.4M$42.5M$51.4M$241.4K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Operating cash flow -$15.2M-$13.9M-$12.8M-$11.9M-$3.2M—
Depreciation and amortisation $32.4K$18.9K$18.3K$5.1K$1.4K—
Stock-based compensation $297.5K$773.7K$592.3K$835.1K$471.2K—
Capital expenditure ——$34.3K$107.1K$21.5K—
Investing cash flow $11.0K—$75.2K-$2.3M-$21.5K—
Financing cash flow $63.5M$4.5M-$3.7M-$3.2M$55.9M—
Buybacks ——$3.7M———

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-036434.

Plot the figures US dollars

  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -30M -20M -10M 0 10M Revenue, FY2021: 15.1K Gross profit, FY2021: -2.2K Net income, FY2021: -2.2M Revenue, FY2022: 486.6K Gross profit, FY2022: 373.4K Net income, FY2022: -13.9M Net income, FY2023: -16M Net income, FY2024: -13.9M Net income, FY2025: -20.4M FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $15.1K $486.6K — — —
Gross profit — -$2.2K $373.4K — — —
Net income — -$2.2M -$13.9M -$16.0M -$13.9M -$20.4M

Recent filings and events

  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Delisting notice Item 3.01
  • Officer or director change Item 5.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%